# Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

> **NCT05554354** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 1 (actual)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic HER2-Negative Breast Carcinoma
- Metastatic Hormone Receptor-Positive Breast Carcinoma

## Interventions

- **DRUG:** Binimetinib
- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography Test
- **DRUG:** Fulvestrant
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Multigated Acquisition Scan

## Key facts

- **NCT ID:** NCT05554354
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-09-13
- **Primary completion:** 2025-04-04
- **Final completion:** 2025-04-04
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Other - slow accrual
- **Last updated:** 2026-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05554354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05554354, "Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05554354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*